Evaluation of different routes of administration and biodistribution of human amnion epithelial cells in mice

Srinivasan, Raghuraman C.; Kannisto, Kristina; Strom, Stephen C.; Gramignoli, Roberto

doi:10.1016/j.jcyt.2018.10.007

Cited by 17 publications

(17 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although tail vein injection is the most widely used transplantation method to deliver cells into a host, most engrafted cells are trapped in the lungs rather than the target organs. For example, splenic injection was a more efficient route of administration of hAECs for targeting the liver than tail vein infusion [ 72 , 73 ]. Therefore, selecting an appropriate transplantation route is vital for cell survival, differentiation of grafted cells, and the recovery of function.…”

Section: Methodsmentioning

confidence: 99%

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Zhang

Lai

2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Human amniotic epithelial cells (hAECs) derived from placental tissues have gained considerable attention in the field of regenerative medicine. hAECs possess embryonic stem cell-like proliferation and differentiation capabilities, and adult stem cell-like immunomodulatory properties. Compared with other types of stem cell, hAECs have special advantages, including easy isolation, plentiful numbers, the obviation of ethical debates, and non-immunogenic and non-tumorigenic properties. During the past two decades, the therapeutic potential of hAECs for treatment of various diseases has been extensively investigated. Accumulating evidence has demonstrated that hAEC transplantation helps to repair and rebuild the function of damaged tissues and organs by different molecular mechanisms. This systematic review focused on summarizing the biological characteristics of hAECs, therapeutic applications, and recent advances in treating various tissue injuries and disorders. Relevant studies published in English from 2000 to 2020 describing the role of hAECs in diseases and phenotypes were comprehensively sought out using PubMed, MEDLINE, and Google Scholar. According to the research content, we described the major hAEC characteristics, including induced differentiation plasticity, homing and differentiation, paracrine function, and immunomodulatory properties. We also summarized the current status of clinical research and discussed the prospects of hAEC-based transplantation therapies. In this review, we provide a comprehensive understanding of the therapeutic potential of hAECs, including their use for cell replacement therapy as well as secreted cytokine and exosome biotherapy. Moreover, we showed that the powerful immune-regulatory function of hAECs reveals even more possibilities for their application in the treatment of immune-related diseases. In the future, establishing the optimal culture procedure, achieving precise and accurate treatment, and enhancing the therapeutic potential by utilizing appropriate preconditioning and/or biomaterials would be new challenges for further investigation.

show abstract

Section: Methodsmentioning

confidence: 99%

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Zhang

Lai

2020

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…As the use of MSCs is intended to alleviate ARDS due to cytokine storm, the optimal route is supposed to be intravenous. A tracing study in mice, which used an in-vivo imaging system, revealed that 24 h after injection, most of the MSCs will be trapped in the lungs (30-60%), and liver (5-15%) (62). A study on the clinical trial.…”

Section: Discussionmentioning

confidence: 99%

Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia—a regenerative dogma

Siddesh¹,

D²,

Jain³

et al. 2021

Stem Cell Investig

View full text Add to dashboard Cite

With a robust rise in the number of COVID-19 cases, the World Health Organization (WHO) has declared COVID-19 as a pandemic on 11 th March 2020. COVID-19 pandemic has invited global researchers from various biomedical and biotechnological researchers to plan various treatment modalities for combating this pandemic crisis. At present, there is the unavailability of specific treatment modality; however, researchers have thrown light into the exploration of mesenchymal stem cells (MSCs) to therapeutically perquisite in ameliorating immune-mediated progressive worsening in COVID-19 infected patients. Cellular therapy (CT) has revolutionized the treatment of untreatable diseases with a better clinical and functional outcome. Placenta, being considered as medical waste, contains a variety of stem cells, and hence placenta-derived MSCs (P-MSCs) owe potentiality for extrapolation to combat COVID-19 pandemic.The usage of P-MSCs in combating the COVID-19 pandemic has plausible challenges in terms of isolation, harvesting, expansion, characterization, and involvement of ethical concerns. This article provides an insight into dealing COVID-19 pandemic with P-MSCs as cell-based therapy embracing immunomodulatory and immune-privileged potentials and future prospects. Advocating prospective randomized controlled clinical trials ethically will concretely supplement for its efficacy and safety concerns.

show abstract

“…Moreover, both mesenchymal and epithelial amniotic cells lack of cell surface histocompatibility complex (HLA) class II and T cell costimulatory molecules, rendering them immunoprivileged. These characteristics allowed to deliver hAC across the immunologic barriers of allo- and xenogeneic transplant recipients, without pharmacological immunosuppression ( 14 , 15 ). This makes it possible to carry out pre-clinical animal experiments creating conditions more closely related to the human transplantations.…”

Section: Discussionmentioning

confidence: 99%

Immunosuppressive Potential of Activated Human Amniotic Cells in an Experimental Murine Model of Skin Allo- and Xenotransplantation

2021

View full text Add to dashboard Cite

Isolated human amniotic cells (hAC) could be used as a source of immunomodulatory factors in regenerative medicine and transplantation. However, in previous experimental studies, native hAC administered to skin graft recipients did not induce graft immunotolerance. To strengthen the immunomodulatory properties of hAC prior to administration to the recipient, we activated them ex vivo using pro-inflammatory cytokines. In this study, we compared the transplantation efficiency of skin allografts (mouse to mouse) and xnografts (rat to mouse) in recipient mice divided into three main groups receiving: 1. Placebo (control group); 2. Cyclosporine A (CsA) [10 or 50 mg/kg body weight (bw)]; 3. suspension of hAC activated ex vivo by IL-1β and INFγ, administered into a tail vein or subcutaneously. During 15 days of observation, hAC administered intravenously or subcutaneously after allotransplantation appeared to be as safe and efficient as CsA at the dose of 10 mg/kg bw in preventing rejection of skin allo- and xenografts. After xenotransplantation, however, only hAC administered intravenously prevented rejection to an extent comparable to CsA. Both CsA (10 mg/kg bw) and activated hAC reduced inflammatory infiltration in the skin (after intravenous injection) and did not increase the concentration of the inflammation marker SAP in serum or percentage of leukocytes in blood. Finally, we concluded that administration of activated hAC is safe and efficient in the presented animal model of skin allo- and xenotransplantation in a route-dependent manner. Activated hAC injected intravenously exhibit an immunosuppressive effect comparable to CsA administered at the dose of 10 mg/kg bw in both allo- and xenotransplantation.

show abstract

Evaluation of different routes of administration and biodistribution of human amnion epithelial cells in mice

Cited by 17 publications

References 98 publications

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia—a regenerative dogma

Immunosuppressive Potential of Activated Human Amniotic Cells in an Experimental Murine Model of Skin Allo- and Xenotransplantation

Contact Info

Product

Resources

About